{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:25Z","timestamp":1792790425457,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an established treatment for peripheral T-cell lymphoma (PTCL), particularly for patients with relapsed\/refractory (r\/r) disease. We aimed to retrieve novel information on the role of histology, disease status prior to transplantation, and donor choice for patients with PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase (ALK)-negative ALCL. We compared imaging by computed tomography (CT) or positron emission tomography (PET) for defining disease status prior to allo-SCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible were adult patients with PTCL-NOS, AITL, and ALK-negative ALCL undergoing allo-SCT between 2010 and 2022 and reported to EBMT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1958 patients underwent allo-SCT. Of patients with known number of prior lines of therapies (n\u2009=\u20091310), 301 (23%), 431 (32.9%) and 578 (44.1%) patients received allo-SCT after one (1L), two (2L) or three or more therapy lines (3L\u2009+), respective. Three-year GvHD-free, relapse-free survival (GRFS), progression-free survival (PFS) and overall survival (OS) were 35.8%, 50.9% and 56.8%, respectively. Three-year relapse incidence (RI) and non-relapse mortality were 25.1% and 24.1%, respectively. In multivariate analysis, histology other than AITL, no complete response (CR) at transplantation, having a haploidentical donor and higher age at allo-SCT resulted in significantly lower PFS and\/or OS. Prior autologous SCT had no impact on the results of allo-SCT and major outcomes did not significantly change when the analyses were restricted to the patients with PET-based response at allo-SCT. Patients allografted in partial response (PR) or SD\/PD still achieved long-term survival with a 3-year PFS\/OS of 46%\/53.7% and 39.6%\/43.6%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Allo-SCT is a valid treatment option in relapsed\/refractory PTCL where targeted therapies still play a limited role. Patients with AITL survived significantly better than patients with PTCL NOS or ALK-negative ALCL following a significantly lower RI, also when comparing CR\/complete metabolic response (CMR) and PR patients separately. Higher age and non-CR at allo-SCT are associated with worse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-026-01783-w","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:05:55Z","timestamp":1771657555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party"],"prefix":"10.1186","volume":"19","author":[{"given":"Evgenii","family":"Shumilov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Ngoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Berning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kroschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Valkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Kinsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore Sicre","family":"de Fontbrune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wagner-Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arain","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"25","key":"1783_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1783_CR2","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.3324\/haematol.2018.213512","volume":"104","author":"D Sibon","year":"2019","unstructured":"Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019;104(12):e562\u20135.","journal-title":"Haematologica"},{"issue":"19","key":"1783_CR3","first-page":"2646","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137(19):2646\u201356.","journal-title":"Blood"},{"issue":"25","key":"1783_CR4","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d'Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1783_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","volume":"35","author":"GG Wulf","year":"2021","unstructured":"Wulf GG, Altmann B, Ziepert M, D\u2019Amore F, Held G, Greil R, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial. Leukemia. 2021;35(1):143\u201355.","journal-title":"Leukemia"},{"issue":"3","key":"1783_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/hon.2144","volume":"33","author":"I Biasoli","year":"2015","unstructured":"Biasoli I, Cesaretti M, Bellei M, Maiorana A, Bonacorsi G, Quaresima M, et al. Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry. Hematol Oncol. 2015;33(3):147\u201351.","journal-title":"Hematol Oncol"},{"issue":"7","key":"1783_CR7","first-page":"1191","volume":"103","author":"B Monica","year":"2018","unstructured":"Monica B, Francine MF, Andrei RS, Steven MH, Luigi M, Won Seog K, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective. Int T-Cell Project Haematol. 2018;103(7):1191\u20137.","journal-title":"Int T-Cell Project Haematol"},{"issue":"5","key":"1783_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.14477","volume":"176","author":"D Chihara","year":"2017","unstructured":"Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176(5):750\u20138.","journal-title":"Br J Haematol"},{"issue":"10168","key":"1783_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet"},{"key":"1783_CR10","unstructured":"NCCN Guidelines. T-Cell Lymphomas. Version 02.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf. Nov 11 2025."},{"issue":"4","key":"1783_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1080\/10428194.2024.2438805","volume":"66","author":"E Shumilov","year":"2025","unstructured":"Shumilov E, Levien L, Mazzeo P, Jung W, Leha A, Koch R, et al. Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning. Leuk Lymphoma. 2025;66(4):668\u201379.","journal-title":"Leuk Lymphoma"},{"issue":"32","key":"1783_CR12","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1200\/JCO.24.00554","volume":"42","author":"O Tournilhac","year":"2024","unstructured":"Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, et al. Long-term follow-up of the prospective randomized AATT study (autologous or allogeneic transplantation in patients with peripheral T-cell lymphoma). J Clin Oncol. 2024;42(32):3788\u201394.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1783_CR13","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"1783_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295\u2013304.","journal-title":"Transplantation"},{"issue":"3","key":"1783_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/leu.2011.230","volume":"26","author":"TH Terwey","year":"2012","unstructured":"Terwey TH, Vega-Ruiz A, Hemmati PG, Martus P, Dietz E, le Coutre P, et al. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia. 2012;26(3):536\u201342.","journal-title":"Leukemia"},{"issue":"6","key":"1783_CR16","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","volume":"11","author":"J Dupuis","year":"2024","unstructured":"Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, et al. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematol. 2024;11(6):e406\u201314.","journal-title":"Lancet Haematol"},{"issue":"14","key":"1783_CR17","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1200\/JCO.23.01687","volume":"42","author":"V Camus","year":"2024","unstructured":"Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas R-O, Ysebaert L, et al. Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: final analysis of the Ro-CHOP trial. J Clin Oncol. 2024;42(14):1612\u20138.","journal-title":"J Clin Oncol"},{"key":"1783_CR18","volume-title":"Autologous stem cell transplantation in major T-cell lymphoma entities: an analysis by the EBMT Lymphoma Working Party","author":"E Shumilov","year":"2025","unstructured":"Shumilov E, Ngoya M, Berning B, Khvedelidze I, Serroukh Y, Wondergem M, et al. Autologous stem cell transplantation in major T-cell lymphoma entities: an analysis by the EBMT Lymphoma Working Party. Hemasphere.in Press; 2025."},{"issue":"5","key":"1783_CR19","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41375-022-01545-w","volume":"36","author":"K Kameda","year":"2022","unstructured":"Kameda K, Kako S, Kim S-W, Usui Y, Kato K, Fukuda T, et al. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia. 2022;36(5):1361\u201370.","journal-title":"Leukemia"},{"issue":"3","key":"1783_CR20","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","volume":"6","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022;6(3):920\u201330.","journal-title":"Blood Adv"},{"issue":"1","key":"1783_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","volume":"12","author":"N Epperla","year":"2019","unstructured":"Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, et al. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019;12(1):6.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1783_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","volume":"13","author":"AC Mamez","year":"2020","unstructured":"Mamez AC, Dupont A, Blaise D, Chevallier P, Forcade E, Ceballos P, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). J Hematol Oncol. 2020;13(1):56.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1783_CR23","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2352-3026(25)00073-0","volume":"12","author":"G Damaj","year":"2025","unstructured":"Damaj G, Bazarbachi A, Berning P, Cottereau A-S, Fox CP, Kyriakou C, et al. Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Haematol. 2025;12(7):e542\u201354.","journal-title":"Lancet Haematol"},{"issue":"6","key":"1783_CR24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.annonc.2025.01.023","volume":"36","author":"F d\u2019Amore","year":"2025","unstructured":"d\u2019Amore F, Federico M, de Leval L, Ellin F, Hermine O, Kim WS, et al. Peripheral T- and natural killer-cell lymphomas: ESMO-EHA clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(6):626\u201344.","journal-title":"Ann Oncol"},{"issue":"1","key":"1783_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1182\/blood-2023-173179","volume":"142","author":"B Glass","year":"2023","unstructured":"Glass B, Altmann B, Stelljes M, Lenz G, Marx J, Hasenkamp J, et al. Results of the astral study: a prospective phase ii clinical study of the german lymphoma alliance to assess the efficacy and toxicity of high-dose chemotherapy followed by allogeneic stem cell transplantation as treatment of primary progressive and relapsed aggressive non-hodgkin lymphoma. Blood. 2023;142(1):231.","journal-title":"Blood"},{"issue":"5","key":"1783_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41409-025-02522-4","volume":"60","author":"I Kr\u00e4mer","year":"2025","unstructured":"Kr\u00e4mer I, K\u00f6nig L, Luft T, Hegenbart U, Sch\u00f6nland S, Eichkorn T, et al. Intermediate-dose TBI\/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma. Bone Marrow Transplant. 2025;60(5):581\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"1783_CR27","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41375-023-01924-x","volume":"37","author":"P Berning","year":"2023","unstructured":"Berning P, Schmitz N, Ngoya M, Finel H, Boumendil A, Wang F, et al. Allogeneic hematopoietic stem cell transplantation for NK\/T-cell lymphoma: an international collaborative analysis. Leukemia. 2023;37(7):1511\u201320.","journal-title":"Leukemia"},{"key":"1783_CR28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210100","volume":"144","author":"IE Karsten","year":"2024","unstructured":"Karsten IE, Schmitz N, Fekom M, de Leval L, Finel H, Khvedelidze I, et al. Hematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT lymphoma working party. Blood. 2024;144:399.","journal-title":"Blood"},{"issue":"2","key":"1783_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","volume":"3","author":"N Mehta-Shah","year":"2019","unstructured":"Mehta-Shah N, Ito K, Bantilan K, Moskowitz AJ, Sauter C, Horwitz SM, et al. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood Adv. 2019;3(2):187\u201397.","journal-title":"Blood Adv"},{"issue":"3","key":"1783_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/hon.2697","volume":"38","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, Rekowski J, M\u00fcller SP, Hertenstein B, Franzius C, Ganser A, et al. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. Hematol Oncol. 2020;38(3):244\u201356.","journal-title":"Hematol Oncol"},{"issue":"6","key":"1783_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jtct.2021.03.014","volume":"27","author":"S Novelli","year":"2021","unstructured":"Novelli S, Bento L, Garcia I, Prieto L, L\u00f3pez L, Gutierrez G, et al. Allogeneic stem cell transplantation in mature t cell and natural killer\/T neoplasias: a registry study from spanish GETH\/GELTAMO centers. Transplant and Cellular Ther. 2021;27(6):493-e1.","journal-title":"Transplant and Cellular Ther"},{"issue":"6","key":"1783_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41409-018-0360-9","volume":"54","author":"G Wulf","year":"2019","unstructured":"Wulf G, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M, et al. Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transplant. 2019;54(6):877\u201384.","journal-title":"Bone Marrow Transplant"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01783-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01783-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01783-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:21:47Z","timestamp":1771856507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01783-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1783"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01783-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"27 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Stelljes: Consulting\/Advisory Role: Pfizer, MSD, Bristol-Myers Squibb, Incyte, Takeda, Astellas, Autolus, Sanofi and Amgen; speaker honoraria: Medac, MSD, Astellas, Jazz Pharmaceuticals, Amgen, Novartis, Gilead, Celgene, BMS, AbbVie, and Incyte; Reseach funding: Pfizer; Conferences\/Travel support: Medac, Sanofi and Pfizer. R. Zeiser: Consulting\/Advisory Role: Novartis, Sanofi, Incyte, medac and Therakos. F. Ayuk: Honoraria: AbbVie, BMS, Kite\/Gilead, Janssen, Therakos, Miltenyi Biomedicine, Novartis, Takeda, Medac, Neovii; Research funding: Therakos, Neovii G. Lenz: received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. G.L. received honoraria not related to this study from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal\/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi. P. Dreger: consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speaker honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. P Dreger is current chairman of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (DAG-HSZT). A. Sureda: Consultancy: Takeda, Abbvie, GenMab, MSD, BMS Celgene, Gilead Kite, Allogene, Autolus, Roche, Novartis; Speakers Bureau: Takeda; Travel: Janssen, Takeda, Gilead Kite, Abbvie. Speaker honoraria: Takeda, BMS Celgene, GenMab, Abbvie, Janssen, Gilead Kite, Vertex, Sanofi; Research support: Takeda, BMS Celgene; A. Sureda is the current President of the EBMT. G. Damaj: Honoraria: Takeda, Amgen. Travel support: Takeda. Research Support: Takeda, Ideogen. A. Bazarbachi: Speaker bureau or advisory board: Novartis, Roche, Sanofi, Jazz, Adienne, Astellas, Takeda, Hikma, Celgene, Jansen, MSD, Abbvie, Pfizer and Amgen. Research support: Novartis, Roche, Takeda, Jansen, Astellas, Celgene, Pfizer and Amgen. N. Schmitz: Honoraria: Gilead Kite, Roche. Travel support: Beigene, Glilead Kite, Roche Research support: Astra Zeneca, Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}